FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Rose

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Fiona Simpkins; Sajeena G Thomas; Alexandra Windhorn; Fadi AbuShahin; Jamie N Bakkum-Gamez; Heidi Frasure; Charles Kunos; Lisa Landrum; Andrea Mariani; Chad Michener; Kathleen Moore; Andrea Papadia; Peter G Rose
Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
Kathleen N Moore; Peter G Rose; Russell J Schilder; Michael W Sill; Higinia R. Cardenes; Koen De Geest; John H Farley; Robert S Mannel; Carolyn McCourt; David S Miller; Paula M Fracasso
A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.
Robert L Coleman; Michael Deavers; Charles W Drescher; Amanda Fader; Neil J Finkler; Andrew K Godwin; James S Hoffman; Wei Hu; Heather A Lankes; D Scott McMeekin; Peter G Rose; Michael W Sill; R Katherine Alpaugh; Gregory P Sutton; Anil K Sood
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Rose (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Fiona Simpkins; Sajeena G Thomas; Alexandra Windhorn; Fadi AbuShahin; Jamie N Bakkum-Gamez; Heidi Frasure; Charles Kunos; Lisa Landrum; Andrea Mariani; Chad Michener; Kathleen Moore; Andrea Papadia; Peter G Rose
Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2013;23(1):98-104.
2012: Kathleen N Moore; Peter G Rose; Russell J Schilder; Michael W Sill; Higinia R. Cardenes; Koen De Geest; John H Farley; Robert S Mannel; Carolyn McCourt; David S Miller; Paula M Fracasso
A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.
Gynecologic oncology 2012;127(3):456-61.
2012: Robert L Coleman; Michael Deavers; Charles W Drescher; Amanda Fader; Neil J Finkler; Andrew K Godwin; James S Hoffman; Wei Hu; Heather A Lankes; D Scott McMeekin; Peter G Rose; Michael W Sill; R Katherine Alpaugh; Gregory P Sutton; Anil K Sood
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Gynecologic oncology 2012;127(3):538-43.
2012: D Scott McMeekin; Michael L Pearl; Peter G Rose; Stephen C Rubin; Michael W Sill; Laurie Small; Ovadia Abulafia; Kathleen M Darcy; Parviz Hanjani; Doris M Benbrook
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.
Gynecologic oncology 2012;127(2):356-61.
2012: Peter G Rose
Which is the best foot to put forward in recurrent ovarian cancer?
Cancer 2012;118(13):3229-31.
2012: Peter G Rose; Ritu Salani; Michael W Sill; Aaron H Wolfson; S Diane Yamada; Amina Ahmed; Nancy Fusco; D Scott McMeekin; Paula M Fracasso
A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.
Gynecologic oncology 2012;125(1):158-62.
2011: K M Moxley; David G Mutch; Peter G Rose; J C Schink; E Berry; A S Case; Dennis S Chi; Amanda Fader; C H Kim; Kathleen N Moore
Malignant melanoma of the vulva: an extension of cutaneous melanoma?
Gynecologic oncology 2011;122(3):612-7.
2011: Peter G Rose
Combination therapy: New treatment paradigm for locally advanced cervical cancer?
Nature reviews. Clinical oncology 2011;8(7):388-90.
2011: Peter G Rose; Shamshad Ali; Charles W Whitney; Rachelle Lanciano; Frederick B Stehman
Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a Gynecologic Oncology Group study.
Gynecologic oncology 2011;121(3):542-5.
2011: Peter G Rose; Mark F Brady
EORTC 55971: does it apply to all patients with advanced state ovarian cancer?
Gynecologic oncology 2011;120(2):300-1.
2011: Malgorzata E Skaznik-Wikiel; Stefanie M Ueda; Heidi E Frasure; Peter G Rose; Aimee Fleury; Francis C Grumbine; Amanda Fader
Abnormal cervical cytology in the diagnosis of uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype?
Acta cytologica 2011;55(3):255-60.
2011: Vivian E von Gruenigen; Steven E Waggoner; Heidi E Frasure; Mary Beth Kavanagh; Jeffrey W Janata; Peter G Rose; Kerry S Courneya; Edith Lerner
Lifestyle challenges in endometrial cancer survivorship.
Obstetrics and gynecology 2011;117(1):93-100.
2011: Peter G Rose; Bradley J Monk; Diane Provencher; Jean Hartney; Philippe Legenne; Stephen Lane
An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer.
Gynecologic oncology 2011;120(1):38-42.
2010: Amanda Fader; Nabila Rasool; Susan A J Vaziri; Toshiyuki Kozuki; Pieter W Faber; Paul Elson; Charles V Biscotti; Chad Michener; Peter G Rose; Luis A Rojas-Espaillat; Jerome L Belinson; Mahrukh K Ganapathi; Ram Ganapathi
CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes.
Anticancer research 2010;30(12):4791-8.
2010: Nabila Rasool; Peter G Rose
Fertility-preserving surgical procedures for patients with gynecologic malignancies.
Clinical obstetrics and gynecology 2010;53(4):804-14.
2010: Matthew A Powell; Virginia L Filiaci; Peter G Rose; Robert S Mannel; Parviz Hanjani; Koen DeGeest; Brigitte E Miller; Nobuyuki Susumu; Frederick R Ueland
Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(16):2727-31.
2010: Vivian E von Gruenigen; Helen Q Huang; Karen M Gil; Heidi E Gibbons; Bradley J Monk; Peter G Rose; Deborah K Armstrong; David Cella; Lari Wenzel
A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study.
Journal of pain and symptom management 2010;39(5):839-46.
2010: Peter G Rose; Shamshad Ali; Charles W Whitney; Rachelle Lanciano; Frederick B Stehman
Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study.
Gynecologic oncology 2010;117(2):270-5.
2010: Nabila Rasool; Amanda Fader; Leigh Seamon; Nikki L Neubauer; Fadi Abu Shahin; Heather A Alexander; Kathleen Moore; Katherine Moxley; Angeles Alvarez Secord; Charles Kunos; Peter G Rose; David M O'Malley
Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence.
Gynecologic oncology 2010;116(1):10-4.
2009: Margaret Liotta; Peter G Rose; Pedro F Escobar
Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer.
Gynecologic oncology 2009;115(2):308-9.
2009: Amanda Fader; David Starks; Paola A Gehrig; Angeles Alvarez Secord; Heidi E Frasure; David M O'Malley; Erin R Tuller; Peter G Rose; Laura Havrilesky; Kathleen N Moore; Warner K Huh; Allison E Axtell; Joseph L Kelley; Kristine M Zanotti
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
Gynecologic oncology 2009;115(2):244-8.
2009: Vivian E von Gruenigen; Helen Q Huang; Karen M Gil; Heidi E Gibbons; Bradley J Monk; Peter G Rose; Deborah K Armstrong; David Cella; Lari Wenzel
Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials.
Cancer 2009;115(20):4857-64.
2009: Charles Kunos; Chunqiao Tian; Steven Waggoner; Peter G Rose; Rachelle Lanciano
Retrospective analysis of concomitant Cisplatin during radiation in patients aged 55 years or older for treatment of advanced cervical cancer: a gynecologic oncology group study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(7):1258-63.
2009: Amanda Fader; Peter G Rose
Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(7):1281-3.
2009: Amanda Fader; Christa Nagel; Allison E Axtell; Kristine Zanotti; Joseph L Kelley; Kathleen N Moore; Angeles Alvarez Secord; Christine S Walsh; Warner K Huh; Paola A Gehrig; Heidi Gibbons; Peter G Rose; Laura Havrilesky; Erin Tuller; Richard D Drake; Justin Bottsford-Miller; David M O'Malley
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
Gynecologic oncology 2009;112(3):558-62.
2009: Behiye P C Goksedef; Charles Kunos; Jerome L Belinson; Peter G Rose
Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB2 cervical carcinoma.
American journal of obstetrics and gynecology 2009;200(2):175.e1-5.
2008: Peter G Rose; Mary Smrekar; Pam Haba; Nancy Fusco; Michael Rodriguez
A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
American journal of clinical oncology 2008;31(5):476-80.
2008: Mark A Morgan; Kathleen M Darcy; Peter G Rose; Koen DeGeest; Michael A Bookman; James K Aikins; Michael W Sill; Robert S Mannel; Cecilia Allievi; Merrill J Egorin
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.
Gynecologic oncology 2008;110(3):329-35.
2008: Michael A Gold; Chunqiao Tian; Charles W Whitney; Peter G Rose; Rachelle Lanciano
Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group Study.
Cancer 2008;112(9):1954-63.
2008: William E Winter; G Larry Maxwell; Chunqiao Tian; Michael J Sundborg; G Scott Rose; Peter G Rose; Stephen C Rubin; Franco Muggia; William P McGuire
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):83-9.
2007: Kathleen N Moore; Katherine M Moxley; Amanda Fader; Allison E Axtell; Rodney P Rocconi; Lisa N Abaid; Ilana Cass; Peter G Rose; Charles A Leath; Teresa Rutledge; Derek Blankenship; Michael A Gold
Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.
Gynecologic oncology 2007;107(3):398-403.
2007: Amanda Fader; Jennifer Brainard; Peter G Rose
Symptomatic vaginal bleeding in a postmenopausal woman: a case report of pancreatic adenocarcinoma metastasizing exclusively to the vagina.
American journal of obstetrics and gynecology 2007;197(5):e8-9.
2007: Peter G Rose; Koen DeGeest; Scott McMeekin; Nancy Fusco
A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study.
Gynecologic oncology 2007;107(2):274-9.
2007: Fiona Simpkins; Jerome Belinson; Peter G Rose
Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
Gynecologic oncology 2007;107(1):118-23.
2007: William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3621-7.
2007: Amanda Fader; Peter G Rose
Role of surgery in ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(20):2873-83.
2007: Peter G Rose; Shamshad Ali; Edwin Watkins; J Tate Thigpen; Gunter Deppe; Daniel L Clarke-Pearson; Samuel Insalaco
Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2804-10.
2007: Fadi Abushahin; Peter G Rose
Role of gemcitabine in the treatment of ovarian cancer.
Women's health (London, England) 2007;3(3):279-90.
2007: William C McBee; Jennifer Brainard; Joram Sawady; Peter G Rose
Yolk sac tumor of the ovary associated with endometrioid carcinoma with metastasis to the vagina: a case report.
Gynecologic oncology 2007;105(1):244-7.
2007: Peter G Rose; Benjamin E Greer; Ira R Horowitz; Maurie Markman; Nancy Fusco
Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Gynecologic oncology 2007;104(1):114-9.
2006: Paul A DiSilvestro; Joan L Walker; Astrid Morrison; Peter G Rose; Howard D Homesley; David Warshal
Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group.
Gynecologic oncology 2006;103(3):1038-42.
2006: Peter G Rose; John A Blessing; Shashikant Lele; Ovadia Abulafia
Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Gynecologic oncology 2006;102(2):210-3.
2006: Peter G Rose; Maurie Markman; Jeffrey G Bell; Nancy Fusco
Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.
Gynecologic oncology 2006;102(2):236-9.
2006: Andrew E Green; Peter G Rose
Pegylated liposomal doxorubicin in ovarian cancer.
International journal of nanomedicine 2006;1(3):229-39.
2005: Pedro F Escobar; Peter G Rose
Docetaxel in ovarian cancer.
Expert opinion on pharmacotherapy 2005;6(15):2719-26.
2005: Peter G Rose; Mary Smrekar; Pamela Haba; Christina Visser; John F Beeler
A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.
Gynecologic oncology 2005;99(3):714-9.
2005: Luis A Rojas-Espaillat; Peter G Rose
Management of locally advanced cervical cancer.
Current opinion in oncology 2005;17(5):485-92.
2005: Robert Kim; Peter G Rose
Surgical staging of gynecologic malignancies: the role of laparoscopy and sentinel node technology.
Surgical oncology clinics of North America 2005;14(2):267-88.
2005: Peter G Rose
Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
The oncologist 2005;10(3):205-14.
2005: Peter G Rose; Mary Smrekar; Nancy Fusco
A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
Gynecologic oncology 2005;96(2):296-300.
2005: J Tate Thigpen; Carol Aghajanian; David S Alberts; Susana Campos; Alan N Gordon; Maurie Markman; D Scott McMeekin; Bradley J Monk; Peter G Rose
Role of pegylated liposomal doxorubicin in ovarian cancer.
Gynecologic oncology 2005;96(1):10-8.
2004: Peter G Rose; Stacy Nerenstone; Mark F Brady; Daniel L Clarke-Pearson; George Olt; Stephen C Rubin; David H Moore; James M Small
Secondary surgical cytoreduction for advanced ovarian carcinoma.
The New England journal of medicine 2004;351(24):2489-97.
2004: Katherine Y Look; Alan B Sandler; John A Blessing; Joseph Lucci; Peter G Rose
Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.
Gynecologic oncology 2004;92(2):644-7.
2003: Peter G Rose; Mary Smrekar
Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel.
Gynecologic oncology 2003;91(2):423-5.
2003: Peter G Rose
Stage IIB-IVA cancer of the cervix.
Cancer journal (Sudbury, Mass.) 2003;9(5):404-14.
2003: Peter G Rose; Nancy Fusco; Mary Smrekar; Kim Mossbruger; Michael Rodriguez
Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity.
Gynecologic oncology 2003;89(3):429-33.
2003: Peter G Rose
Combined-modality therapy of locally advanced cervical cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10 Suppl):211s-217s.
2003: Stephen A Cannistra; Robert C Bast; Jonathan S Berek; Michael A Bookman; Christopher P Crum; Paul D DePriest; Judy E Garber; Wui-Jin Koh; Maurie Markman; William P McGuire; Peter G Rose; Eric K Rowinsky; Gordon J S Rustin; Steven J Skates; Paul A Vasey; Laura King
Progress in the management of gynecologic cancer: consensus summary statement.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10 Suppl):129s-132s.
2003: Peter G Rose; John A Blessing; Richard E Buller; Robert S Mannel; Kenneth D Webster
Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Gynecologic oncology 2003;89(2):267-70.
2003: Peter G Rose; John A Blessing; Harrison G Ball; James Hoffman; David Warshal; Koen DeGeest; David H Moore
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.
Gynecologic oncology 2003;88(2):130-5.
2003: Peter G Rose; Kim Mossbruger; Nancy Fusco; Mary Smrekar; Sue Eaton; Michael Rodriguez
Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.
Gynecologic oncology 2003;88(1):17-21.
2002: Andrew E Green; Keith R McCrae; Peter G Rose
Arterial thrombosis in a gynecologic oncology patient: evaluation and management.
Gynecologic oncology 2002;87(2):228-30.
2002: Peter G Rose; Panos T Lappas
Pharmacoeconomics of cisplatin-based chemoradiation in cervical cancer: a review.
Expert opinion on pharmacotherapy 2002;3(9):1245-9.
2002: Peter G Rose; Michael Rodriguez; Joan Walker; Benjamin E Greer; Nancy Fusco; William McGuire
A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Gynecologic oncology 2002;85(1):136-9.
2001: Peter G Rose; J H Maxson; Nancy Fusco; Kim Mossbruger; Michael Rodriguez
Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.
Gynecologic oncology 2001;82(2):323-8.
2001: Peter G Rose; Peter F Faulhaber; FD Miraldi; Fadi W Abdul-Karim
Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy.
Gynecologic oncology 2001;82(1):17-21.
2001: Paula M Fracasso; Mark F Brady; David H Moore; J L Walker; Peter G Rose; L Letvak; T M Grogan; William P McGuire
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(12):2975-82.
2001: Peter G Rose; P J Eifel
Combined radiation therapy and chemotherapy for carcinoma of the cervix.
Cancer journal (Sudbury, Mass.) 2001;7(2):86-94.
2001: J P Curtin; John A Blessing; Kenneth D Webster; Peter G Rose; A R Mayer; Wesley C Fowler; John Malfetano; R D Alvarez
Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1275-8.
2000: Peter G Rose
Chemoradiotherapy: the new standard care for invasive cervical cancer.
Drugs 2000;60(6):1239-44.
2000: Peter G Rose; M Rodriguez; Steven E Waggoner; Benjamin E Greer; Ira R Horowitz; Jeffrey M Fowler; William P McGuire
Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(16):2957-62.
2000: Peter G Rose; B Alvarez; G T Maclennan
Exacerbation of endometriosis as a result of premenopausal tamoxifen exposure.
American journal of obstetrics and gynecology 2000;183(2):507-8.
2000: Peter G Rose; Nahida H Gordon; Nancy Fusco; L Fluellen; Michael Rodriguez; Stephen T Ingalls; Charles L Hoppel
A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
Gynecologic oncology 2000;78(2):228-34.
2000: Peter G Rose; Virginia L Brunetto; L VanLe; J Bell; Joan L Walker; Roger B Lee
A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Gynecologic oncology 2000;78(2):212-6.
2000: Peter G Rose; P T Lappas
Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: implications from five randomized trials.
Gynecologic oncology 2000;78(1):3-6.
1999: Maurie Markman; John A Blessing; Koen DeGeest; M Morgan; Katherine Y Look; T J Herzog; Peter G Rose
Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.
Gynecologic oncology 1999;75(3):444-6.
1999: Peter G Rose; John A Blessing; D M Gershenson; Ramon McGehee
Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2676-80.
1999: Peter G Rose; Brian N Bundy; E B Watkins; J Tate Thigpen; Gunter Deppe; M A Maiman; Daniel L Clarke-Pearson; S Insalaco
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
The New England journal of medicine 1999;340(15):1144-53.
1999: Peter G Rose; V Basile
Palliative sclerosis of intra-abdominal cystic ovarian or peritoneal carcinoma.
Gynecologic oncology 1999;72(2):256-60.
1999: Peter G Rose; LP Adler; Michael Rodriguez; Peter F Faulhaber; Fadi W Abdul-Karim; FD Miraldi
Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):41-5.
1998: Peter G Rose; M H Stoler; Fadi W Abdul-Karim
Papillary squamotransitional cell carcinoma of the vagina.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 1998;17(4):372-5.
1998: Peter G Rose; G Mendelsohn; I Kornbluth
Hysteroscopic dissemination of endometrial carcinoma.
Gynecologic oncology 1998;71(1):145-6.
1998: Peter G Rose; Baha M Arafah; Fadi W Abdul-Karim
Malignant struma ovarii: recurrence and response to treatment monitored by thyroglobulin levels.
Gynecologic oncology 1998;70(3):425-7.
1998: Peter G Rose; John A Blessing; John Soper; J F Barter
Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
Gynecologic oncology 1998;70(2):267-71.
1998: Peter G Rose; John A Blessing; Linda Van Le; Steven E Waggoner
Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Gynecologic oncology 1998;70(2):263-6.
1998: Maurie Markman; Peter G Rose; E Jones; Ira R Horowitz; A Kennedy; Kenneth Webster; Jerome Belinson; Nancy Fusco; L Fluellen; Barbara Kulp; Gertrude Peterson; William P McGuire
Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1849-51.
1998: Peter G Rose; Nancy Fusco; L Fluellen; Michael Rodriguez
Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1494-7.
1998: Peter G Rose; John A Blessing; A R Mayer; Howard D Homesley
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):405-10.
1997: Peter G Rose; Michael Rodriguez; Fadi W Abdul-Karim
Malignant mixed mullerian tumor of the female peritoneum: treatment and outcome of three cases.
Gynecologic oncology 1997;65(3):523-5.
1997: Peter G Rose; F W Abdul-Karim
Isolated appendiceal metastasis in early ovarian carcinoma.
Journal of surgical oncology 1997;64(3):246-7.
1996: Peter G Rose; John A Blessing; G S Lewandowski; William T Creasman; K D Webster
A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
Gynecologic oncology 1996;63(1):101-4.
1996: Peter G Rose
Cerebrovascular embolization of choriocarcinoma.
Obstetrics and gynecology 1996;88(4 Pt 2):738.
1996: Peter G Rose
Operative retroperitoneal ureteral catheterization for obstructive uropathy in primary locally advanced carcinoma of the cervix: description of a technique and experience.
Gynecologic oncology 1996;61(1):79-82.
1996: Peter G Rose
Hyperglycemia secondary to megestrol acetate for endometrial neoplasia.
Gynecologic oncology 1996;61(1):139-41.
1995: Peter G Rose; M S Piver
Intestinal perforation secondary to paclitaxel.
Gynecologic oncology 1995;57(2):270-2.
1995: B A Neary; Peter G Rose
Complete response of a persistent ectopic pregnancy to dactinomycin after methotrexate failure. A case report.
The Journal of reproductive medicine 1995;40(2):160-2.
1994: Peter G Rose; R E Hunter
Advanced ovarian cancer in a woman with a family history of ovarian cancer, discovered at referral for prophylactic oophorectomy. A case report.
The Journal of reproductive medicine 1994;39(11):908-10.
1994: Peter G Rose; R B Rubin; B E Nelson; R E Hunter; F R Reale
Accuracy of frozen-section (intraoperative consultation) diagnosis of ovarian tumors.
American journal of obstetrics and gynecology 1994;171(3):823-6.
1994: Peter G Rose; J M Terrien; Stephen Baker
Plasma D-dimer and peritoneal CA-125 levels as predictors of disease status in ovarian carcinoma.
Journal of surgical oncology 1994;56(3):168-71.
1994: Peter G Rose; R M Sommers; F R Reale; R E Hunter; L Fournier; B E Nelson
Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma.
Obstetrics and gynecology 1994;84(1):12-6.
1994: Peter G Rose; G Wilson
Advanced cervical carcinoma presenting with toxic shock syndrome.
Gynecologic oncology 1994;52(2):264-6.
1993: Peter G Rose; Stephen Baker; M Kern; T J Fitzgerald; W K Tak; F R Reale; B E Nelson; R E Hunter
Primary radiation therapy for endometrial carcinoma: a case controlled study.
International journal of radiation oncology, biology, physics 1993;27(3):585-90.
1993: B L Bjornsson; B E Nelson; F R Reale; Peter G Rose
Accuracy of frozen section for lymph node metastasis in patients undergoing radical hysterectomy for carcinoma of the cervix.
Gynecologic oncology 1993;51(1):50-3.
1993: Peter G Rose; F R Reale
Serous papillary carcinoma of the cervix.
Gynecologic oncology 1993;50(3):361-4.
1993: Peter G Rose; A E Fraire
Multiple primary gynecologic neoplasms in a young HIV-positive patient.
Journal of surgical oncology 1993;53(4):269-72.
1993: Peter G Rose; W K Tak; F R Reale
Squamous cell carcinoma arising in a mature cystic teratoma with metastasis to the paraaortic nodes.
Gynecologic oncology 1993;50(1):131-3.
1993: B E Nelson; Peter G Rose; F R Reale
Isolated parenchymal splenic metastasis in epithelial ovarian cancer.
Gynecologic oncology 1993;50(1):124-7.
1993: Peter G Rose; M S Piver; J H Malfetano; T R Baker; RE Hempling; FO Recio
A phase II study of weekly cisplatin followed by cisplatin and ifosfamide in advanced or recurrent cervical carcinoma.
Cancer 1993;71(7):2245-9.
1993: Peter G Rose; Stephen Baker; L Fournier; B E Nelson; R E Hunter
Serum squamous cell carcinoma antigen levels in invasive cervical cancer: prediction of response and recurrence.
American journal of obstetrics and gynecology 1993;168(3 Pt 1):942-6.
1993: B E Nelson; Peter G Rose
Malignant pericardial effusion from squamous cell cancer of the cervix.
Journal of surgical oncology 1993;52(3):203-6.
1993: Peter G Rose; S H Cheeseman
Advanced ovarian carcinoma managed in an HIV-positive patient.
Gynecologic oncology 1993;48(1):132-4.
1992: Peter G Rose; B E Nelson; F R Reale
False-positive elevation of CA-125 in papillary serous carcinoma of the endometrium treated with postoperative whole abdominal radiation.
Gynecologic oncology 1992;47(1):127-9.
1992: Peter G Rose; B E Nelson; L Fournier; R E Hunter
Serum squamous cell carcinoma antigen levels in invasive squamous vulvar cancer.
Journal of surgical oncology 1992;50(3):183-6.
1992: J U Shim; Peter G Rose; F R Reale; H Soto; W K Tak; R E Hunter
Accuracy of frozen-section diagnosis at surgery in clinical stage I and II endometrial carcinoma.
American journal of obstetrics and gynecology 1992;166(5):1335-8.
1992: Peter G Rose
The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer.
American journal of obstetrics and gynecology 1992;166(3):843-6.
1992: Peter G Rose; S D Cha; W K Tak; T Fitzgerald; F Reale; R E Hunter
Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma.
International journal of radiation oncology, biology, physics 1992;24(2):229-33.
1991: Peter G Rose; F R Reale
Papillary serous carcinoma of the peritoneum following endometrial cancer.
Obstetrics and gynecology 1991;78(5 Pt 2):980-3.
1991: S B Young; Peter G Rose; K L Reuter
Vaginal fibromyomata: two cases with preoperative assessment, resection, and reconstruction.
Obstetrics and gynecology 1991;78(5 Pt 2):972-4.
1991: R E Hunter; T W Griffin; S Stevens; Lynda D Roman; F Bokhari; F R Reale; W K Tak; T J Fitzgerald; M B Dillon; Peter G Rose
High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer.
Cancer 1991;68(9):1890-4.
1991: Peter G Rose; W K Tak; F R Reale; R E Hunter
Adenoid cystic carcinoma of the vulva: a radiosensitive tumor.
Gynecologic oncology 1991;43(1):81-3.
1991: Peter G Rose; F R Reale; A Fisher; R E Hunter
Appendectomy in primary and secondary staging operations for ovarian malignancy.
Obstetrics and gynecology 1991;77(1):116-8.
1990: Peter G Rose; M S Piver
Primary resection of vaginal metastases with the Cavitron ultrasonic surgical aspirator in stage III endometrial carcinoma.
Gynecologic oncology 1990;39(3):264-5.
1990: Peter G Rose; S M Cohen
Methotrexate therapy for persistent ectopic pregnancy after conservative laparoscopic management.
Obstetrics and gynecology 1990;76(5 Pt 2):947-9.
1990: Peter G Rose; Lynda D Roman; F R Reale; W K Tak; R E Hunter
Primary adenocarcinoma of the breast arising in the vulva.
Obstetrics and gynecology 1990;76(3 Pt 2):537-9.
1990: Peter G Rose; F R Reale; C Longcope; R E Hunter
Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer.
Obstetrics and gynecology 1990;76(2):258-63.